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Editorial
Toxoplasmosis: A scenic change and a change of therapy?
The prenatal diagnosis and treatment of congenital 
Toxoplasma gondii (T. gondii) infection is published in 
this issue of European Journal of Obstetrics, Gynecology 
and Reproductive Biology (Schoondermark-van de Ven et
al.).
Using rhesus monkeys the authors studied the trans­
placental transfer of spiramycine and pyrimethamine /sul­
fadiazine and the effect of treatment at proven fetal 
infection. The results of these studies were published in 
paraclinical journals and are also available as a Ph.D. 
Thesis (Toxoplasmosis -  Catholic University, Nijmegen,
NL).
To inform our readers the main results from these 
animal studies are presented as a review article. The results 
are important for clinical diagnosis and treatment.
Toxoplasma infection can have serious consequences for 
the fetus. Severe manifestations are hydrocephalus, mi- 
crocephalus, chorioretinitis, and intracranial calcifications. 
Non-specific symptoms are intra-uterine growth retarda­
tion, hepatospleno-megaly, purpura and jaundice. The
frequency of transmission of toxoplasma infection in­
creases from 17% in the first trimester to 65% in the third 
trimester. The degree of fetal or neonatal morbidity is more 
severe when infection occurs early in pregnancy.
The diagnosis of fetal Toxoplasma infection is now 
greatly facilitated by a novel PCR assay.
Using this PCR the effect of treatment can be monitored. 
Pharmacokinetic studies show that spiramycine, a bacterio­
static macrolide antibiotic, follows a two-compartment 
model in rhesus monkeys. Spiramycine accumulates espe­
cially in the liver and spleen of mother and fetus. The 
concentration of spiramycin in placental tissue appears to 
be 10 to 20 times that of the concentration in fetal serum. 
The concentration of spiramycine in amniotic fluid is about 
five times higher than the concentration in fetal serum. 
Absolutely no spiramycine is found in the fetal brain. 
From these in vivo studies in monkeys one may conclude 
that the placenta acts as a barrier for spiramycine. This is 
also found in dual or open perfusion of the isolated 
cotyledon of the placenta.
Pyrimethamine and sulfadiazine follow a one compart­
ment model in rhesus monkeys. Both drugs cross the 
placenta very well. In addition pyrimethamine is found to 
accumulate in brain tissue with concentrations being three 
to four times higher than the corresponding concentrations 
in serum. Thirty percent of the sulfadiazine is found to 
reach the brain tissue when compared with the corre­
sponding drug concentration in serum.
When administered early after the onset of fetal in­
fection the combination of pyrimethamine/sulfadiazine is 
clearly effective in reducing the number of parasites in the 
fetus or amniotic fluid to undetectable levels. One has to 
realise'however that pyrimethamine and sulfadiazine are 
both strong inhibitors of the enzyme methylene-tetra- 
hydro-folate-reductase (MTHFR) being essential for folate 
metabolism and thus can impair DNA synthesis and RNA 
unless folinic acid is added.
Pyrimethamine and sulfadiazine only attack tachyzoites.
Studies focusing on new drugs crossing the blood-brain 
barrier and acting on cysts as well are already published 
(Araujo et al., Antimicrob Agents Chemother 1991, 35, 
293-299) and seem promising.
In countries with a low prevalence of T. gondii the 
policy is to rely on primary prevention. In countries with a 
high prevalence of T. gondii screening is routinely per­
formed. The improvement of T. gondii prenatal detection 
by the PCR method and the knowledge that pyrimeth­
amine/sulfadiazine/folic acid combination are clearly 
effective in the infected fetus are strong arguments in favor 
of reconsidering the screening in countries that do not have 
a screening programme.
The therapeutic effect of spiramycine in fetal infection is 
not to be expected and should be abandoned.
Because the placenta of the rhesus monkey is also of the 
haemochorial type as in the human, the presented data are 
probably transferable to the human.
T.K.A.B. Eskes 
Chief editor
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